Seattle Genetics announces approval of TUKYSA by the U.S. Food and Drug Administration (FDA).
On April 21st, 2020
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. We look forward to sharing the efficacy and safety data from the HER2CLIMB trial as you consider adding TUKYSA to your formularies.
NDC
TUKYSA
TABLET COUNT
51144-002-60
150 mg
60 tablets per bottle
51144-001-60
50 mg
60 tablets per bottle
Please click here for Full Prescribing Information.
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. We look forward to sharing the efficacy and safety data from the HER2CLIMB trial as you consider adding TUKYSA to your formularies.
| NDC | TUKYSA | TABLET COUNT | ||
| 51144-002-60 | 150 mg | 60 tablets per bottle | ||
| 51144-001-60 | 50 mg | 60 tablets per bottle |
Please click here for Full Prescribing Information.
No comments have been posted yet.